Aspergillosis is an infection caused by Aspergillus, a common mold (a type of fungus) that lives indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, people with weakened immune systems or lung diseases are at a higher risk of developing health problems due to Aspergillus. The types of health problems caused by Aspergillus include allergic reactions, lung infections, and infections in other organs.
DelveInsight’s, “Aspergillosis Pipeline Insights, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Aspergillosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Get free sample page @ https://www.delveinsight.com/sample-request/aspergillosis-pipeline-insight
Some of Aspergillosis Companies are:
- Pulmocide
- Astellas Pharma
- Nektar Therapeutics
- Pulmatrix
- F2G
- Pfizer
- Cellix Bio
- Regeneron Pharmaceuticals/Sanofi
- Scynexis
- Matinas BioPharma
- TFF Pharmaceuticals
- And Many Others
Get free sample page @ https://www.delveinsight.com/sample-request/aspergillosis-pipeline-insight
DelveInsight’s report covers around 50+ products under different phases of clinical development like
- Late-stage products (Phase II and Phase II/III)
- Mid-stage products (Phase II and Phase II/III)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Some of Aspergillosis Therapies:
- PC 945
- Itraconazole inhaled
- Isavuconazole
- Amphotericin B inhalation
- Olorofim
- Anidulafungin/voriconazole
- CLX IFN 59
- Dupilumab
- Ibrexafungerp:
- MAT2203
- TFF VORI
Get free sample page @ https://www.delveinsight.com/sample-request/aspergillosis-pipeline-insight
Table of Contents:
Introduction
Executive Summary
Aspergillosis: Overview
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
Aspergillosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Aspergillosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Aspergillosis Collaboration Deals
Late Stage Products (Phase III)
• Comparative Analysis
Dupilumab: Regeneron Pharmaceuticals/Sanofi
Mid Stage Products (Phase II)
• Comparative Analysis
Ibrexafungerp: Scynexis
PC945: Pulmocide
Early Stage Products (Phase I)
• Comparative Analysis
TFF VORI: TFF Pharmaceuticals
Pre-clinical and Discovery Stage Products
• Comparative Analysis
MAT2203: Matinas BioPharma
Inactive Products
• Comparative Analysis
Aspergillosis Key Companies
Aspergillosis Key Products
Aspergillosis- Unmet Needs
Aspergillosis- Market Drivers and Barriers
Aspergillosis- Future Perspectives and Conclusion
Aspergillosis Analyst Views
Aspergillosis Key Companies
Appendix
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/aspergillosis-pipeline-insight